{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:54:55Z","timestamp":1787644495287,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To develop and validate a model to predict serious infection risk in rheumatoid arthritis (RA) patients initiating biologic or targeted synthetic DMARDs (b\/tsDMARDs), and to implement it as an interactive tool (RAISE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a nationwide cohort study (2010\u20132023) using the French National Health Data System. Adults with RA initiating a b\/tsDMARD were included. The primary outcome was a serious infection (i.e. requiring hospitalization). The dataset was randomly split into a derivation cohort (66%) and a validation cohort (34%) for internal (hold-out) validation. Candidate predictors included demographics, treatment initiated, corticosteroid dose, prior infections and comorbidities. Variable selection used LASSO, followed by a multivariable Cox model to estimate adjusted hazard ratios. In the derivation cohort, 500 bootstrap resamples were used to assess optimism-corrected performance. Model discrimination and calibration (6\u201324\u2009months) were evaluated in both cohorts. No external validation was performed at this stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over median follow-up of 12.5\u2009months (IQR 5.3\u201333.3), 4,657 and 2,359 serious infections occurred in derivation and validation cohorts, respectively. Predictors included rituximab (aHR 2.20, 95% CI 1.98\u20132.44), infliximab (aHR 1.75, 1.56\u20131.97), corticosteroids \u22657.5\u2009mg\/day (aHR 1.45, 1.33\u20131.58), prior infection (aHR 1.62, 1.48\u20131.77), pulmonary disease (aHR 1.51, 1.40\u20131.64) and diabetes (aHR 1.34, 1.23\u20131.46). The model showed moderate discrimination (C-index 0.71) and calibration (mean absolute error \u22640.07).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RAISE delivers personalized 6-, 12-, 18- and 24-month infection risk estimates using routinely available data, improving on the scope and relevance of earlier prediction tools. It enables risk-based treatment planning and preventive strategies, with potential for international adoption following external validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf644","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:54:21Z","timestamp":1764680061000},"source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of a predictive model for the risk of serious infection in patients with rheumatoid arthritis initiating a biologic or targeted synthetic DMARD: a nationwide cohort study"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3288-6014","authenticated-orcid":false,"given":"Mounya","family":"Abboud","sequence":"first","affiliation":[{"name":"EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris Est Cr\u00e9teil University (UPEC) , Cr\u00e9teil,","place":["France"]},{"name":"EPI-PHARE, Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products [ANSM], and French National Health Insurance [CNAM]) , Saint-Denis,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"EPI-PHARE, Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products [ANSM], and French National Health Insurance [CNAM]) , Saint-Denis,","place":["France"]},{"name":"Research Center for Epidemiology and Population Health (CESP), University Paris-Saclay-UVSQ , Versailles,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-5270","authenticated-orcid":false,"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris Est Cr\u00e9teil University (UPEC) , Cr\u00e9teil,","place":["France"]},{"name":"EPI-PHARE, Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products [ANSM], and French National Health Insurance [CNAM]) , Saint-Denis,","place":["France"]},{"name":"Department of Dermatology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Henri Mondor Hospital , Creteil,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2026011114071283100_keaf644-B1","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"2026011114071283100_keaf644-B2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026011114071283100_keaf644-B3","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/rheumatology\/kead515","article-title":"Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?","volume":"63","author":"Lauper","year":"2024","journal-title":"Rheumatology"},{"key":"2026011114071283100_keaf644-B4","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3390\/jcm13103000","article-title":"Incidence rates of infections in rheumatoid arthritis patients treated with Janus kinase or interleukin-6 inhibitors: results of a retrospective, multicenter cohort study","volume":"13","author":"Yoshida","year":"2024","journal-title":"J Clin Med"},{"key":"2026011114071283100_keaf644-B5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","article-title":"Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register","volume":"81","author":"Redeker","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026011114071283100_keaf644-B6","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s10067-024-06980-x","article-title":"Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs","volume":"43","author":"Opdam","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026011114071283100_keaf644-B7","doi-asserted-by":"crossref","first-page":"e0306548","DOI":"10.1371\/journal.pone.0306548","article-title":"Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with Janus kinase inhibitors: a systematic review and meta-analysis. Liu BM, editor","volume":"19","author":"Ouranos","year":"2024","journal-title":"PLoS One"},{"key":"2026011114071283100_keaf644-B8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jmii.2024.08.013","article-title":"Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor","volume":"58","author":"Huang","year":"2025","journal-title":"J Microbiol Immunol Infect"},{"key":"2026011114071283100_keaf644-B9","doi-asserted-by":"crossref","first-page":"e001235","DOI":"10.1136\/rmdopen-2020-001235","article-title":"Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis","volume":"7","author":"Riley","year":"2021","journal-title":"RMD Open"},{"key":"2026011114071283100_keaf644-B10","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026011114071283100_keaf644-B11","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1136\/annrheumdis-2013-203341","article-title":"Evaluation of the RABBIT Risk Score for serious infections","volume":"73","author":"Zink","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026011114071283100_keaf644-B12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10067-020-05425-5","article-title":"Performance of the RABBIT infection risk score in an Argentinian rheumatoid arthritis cohort","volume":"40","author":"Garcia Salinas","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026011114071283100_keaf644-B13","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keaa557","article-title":"Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis","volume":"60","author":"Thomas","year":"2021","journal-title":"Rheumatology"},{"key":"2026011114071283100_keaf644-B14","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026011114071283100_keaf644-B15","doi-asserted-by":"crossref","first-page":"EVIDoa2400275","DOI":"10.1056\/EVIDoa2400275","article-title":"Nirsevimab effectiveness at preventing RSV-related hospitalization in infants","volume":"4","author":"Jabagi","year":"2025","journal-title":"NEJM Evid"},{"key":"2026011114071283100_keaf644-B16","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2026011114071283100_keaf644-B17","doi-asserted-by":"crossref","first-page":"e003865","DOI":"10.1136\/rmdopen-2023-003865","article-title":"Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)","volume":"10","author":"Bastard","year":"2024","journal-title":"RMD Open"},{"key":"2026011114071283100_keaf644-B18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026011114071283100_keaf644-B19","doi-asserted-by":"crossref","first-page":"e003531","DOI":"10.1136\/rmdopen-2023-003531","article-title":"Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System","volume":"10","author":"Jourdain","year":"2024","journal-title":"RMD Open"},{"key":"2026011114071283100_keaf644-B20","doi-asserted-by":"crossref","first-page":"105460","DOI":"10.1016\/j.jbspin.2022.105460","article-title":"Prevalence, mortality, and treatment of patients with rheumatoid arthritis: a cohort study of the French National Health Data System, 2010-2019","volume":"90","author":"Pina Vegas","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2026011114071283100_keaf644-B21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/pds.4006","article-title":"Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database","volume":"25","author":"Sahli","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026011114071283100_keaf644-B22","author":"Dubost","year":"2020"},{"key":"2026011114071283100_keaf644-B23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1186\/s12889-017-4967-3","article-title":"Ability of ecological deprivation indices to measure social inequalities in a French cohort","volume":"17","author":"Temam","year":"2017","journal-title":"BMC Public Health"},{"key":"2026011114071283100_keaf644-B24","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026011114071283100_keaf644-B25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/bimj.201700067","article-title":"Variable selection\u2014a review and recommendations for the practicing statistician","volume":"60","author":"Heinze","year":"2018","journal-title":"Biom J"},{"key":"2026011114071283100_keaf644-B26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the Lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"2026011114071283100_keaf644-B27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"2026011114071283100_keaf644-B28","volume-title":"Regression modeling strategies with applications to linear models, logistic regression, and survival analysis","author":"Harrell","edition":"1st edn"},{"key":"2026011114071283100_keaf644-B29","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-16399-0","volume-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"Steyerberg","year":"2019"},{"key":"2026011114071283100_keaf644-B30","doi-asserted-by":"crossref","first-page":"e003946","DOI":"10.1136\/rmdopen-2023-003946","article-title":"Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis","volume":"10","author":"Song","year":"2024","journal-title":"RMD Open"},{"key":"2026011114071283100_keaf644-B31","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/ard.2009.122226","article-title":"Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity","volume":"69","author":"Solomon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026011114071283100_keaf644-B32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13075-024-03460-0","article-title":"Risk prediction of new-onset thrombocytopenia in patients with systemic lupus erythematosus: a multicenter prospective cohort study based on Chinese SLE treatment and research group (CSTAR) registry","volume":"26","author":"Zhang","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026011114071283100_keaf644-B33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2307\/3002000","article-title":"Limitations of the application of fourfold table analysis to hospital data","volume":"2","author":"Berkson","year":"1946","journal-title":"Biom Bull"},{"key":"2026011114071283100_keaf644-B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.070","article-title":"Statistical association and Berkson\u2019s paradox","author":"Elston","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf644\/65728466\/keaf644.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf644\/65728466\/keaf644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf644\/65728466\/keaf644.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T19:07:22Z","timestamp":1768158442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf644\/8363898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf644","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,3]]},"article-number":"keaf644"}}